Advances in systemic treatment for early breast cancer patients
10.3760/cma.j.cn101721-20241202-00409
- VernacularTitle:早期乳腺癌患者系统治疗研究进展
- Author:
Yujia ZHANG
1
;
Yaqi PENG
1
;
Li MA
1
Author Information
1. 河北医科大学第四医院乳腺中心，石家庄 050011
- Publication Type:Journal Article
- Keywords:
Breast cancer;
Systemic treatment;
Adjuvant therapy;
Neoadjuvant therapy
- From:
Clinical Medicine of China
2025;41(2):99-104
- CountryChina
- Language:Chinese
-
Abstract:
Early-stage treatment of malignant tumors has a significant effect on improving the prognosis. In ASCO and ESMO 2024, several important advancements have been made in the field of systemic therapy for early-stage breast cancer, particularly in the diversification of treatment plans and the individualization of strategies for different molecular subtypes of breast cancer. The importance of adjuvant endocrine therapy (AET) has been highlighted on treating hormone receptor positive/human epidermal growth factor receptor 2 negative early breast cancer.The adjuvant therapy with Cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) has been proven successful in treating HR+/HER2- early breast cancer. Neoadjuvant immunotherapy targeting early triple positive breast cancer (TNBC) has shown unique advantages. The possibility of having down-grade chemotherapy safely in treating HR+/HER2+ stage breast cancer has been explored.
